Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep …
WEB1 day ago · On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA ...
Vivos Therapeutics Receives Groundbreaking FDA 510(k) …
WEB2 days ago · Kirk Huntsman, Chairman and CEO of Vivos, stated, “The FDA 510(k) clearance announced today is, to our knowledge, the first time any oral medical device has ever been approved to treat moderate ...
Vivos Therapeutics Receives Groundbreaking FDA 510(k) …
WEB1 day ago · Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now ...
FDA Clears Vivos Therapeutics Pediatric Sleep Apnea and Snoring …
WEB20 hours ago · Designed to reduce nighttime snoring and treat moderate to severe obstructive sleep apnea in children aged 6 to 17, this Vivos device is intended for those diagnosed with snoring and/or OSA who also require orthodontic treatment. Kirk Huntsman, Chairman and CEO of Vivos, said, “The FDA 510 (k) …
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for …
WEBNov 29, 2023 · Vivos Therapeutics announces the first ever FDA clearance for treating severe obstructive sleep apnea (OSA) with removable oral appliances. The Vivos CARE appliances reposition and expand the airway without surgery or CPAP, offering a non-invasive and effective alternative treatment.
Vivos Therapeutics Announces Pricing of $4.3 Million
WEB22 hours ago · LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...
Vivos Therapeutics Gets FDA 510(k) Clearance To Treat Pediatric …
WEB1 day ago · Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring GlobeNewswire 1h Vivos Therapeutics GAAP EPS of -$0.60, revenue of $4.1M
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric
WEB2 days ago · The FDA has granted 510(k) clearance to Vivos Therapeutics' DNA oral appliance for treating moderate to severe obstructive sleep apnea and snoring in children aged 6-17.
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for …
WEBNov 29, 2023 · Vivos Therapeutics, Inc. With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue ...
Vivos Therapeutics Announces Positive Results From 7-Month …
WEBJun 27, 2024 · The pilot program results announced today provide evidence of the significant potential of this new model for Vivos. The pilot program was conducted over a 7-month period in seven dental offices and one ear, nose, and throat specialist office located across several states with highly diverse patient demographic profiles.